CN1075960A - Amino benzoyl guanidine, its preparation method that replaces is as the purposes and the medicament that contains it of medicine - Google Patents
Amino benzoyl guanidine, its preparation method that replaces is as the purposes and the medicament that contains it of medicine Download PDFInfo
- Publication number
- CN1075960A CN1075960A CN 93101526 CN93101526A CN1075960A CN 1075960 A CN1075960 A CN 1075960A CN 93101526 CN93101526 CN 93101526 CN 93101526 A CN93101526 A CN 93101526A CN 1075960 A CN1075960 A CN 1075960A
- Authority
- CN
- China
- Prior art keywords
- formula
- guanidine
- benzoyl guanidine
- pyrrolidyl
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention has narrated benzoyl guanidine and the pharmaceutical salts thereof of formula I, and R in the formula (1) or R (2) they are amido-NR (3) R (4), and R (3) and R (4) they are H, cycloalkyl, or R (3) is phenyl-(CH
2)
p-, p=0,1,2,3 or 4, or phenyl, or R (3) and R (4) can be methene chain jointly also; R (1) or R (2) also can be other substituting group: H, F, Cl, alkyl, alkoxyl group, CF
3, CmF
2M+
1-CH
2-, benzyl or phenoxy group.The compounds of this invention shows good anti-arrhythmia character, for example situation about occurring in anoxic.These compounds have the cardioprotection of the prevention and the treatment of myocardial infarction as anti-arrhythmic.
Description
The present invention relates to the benzoyl guanidine and the pharmaceutical salts thereof of formula I:
In the formula
R(1) or R(2) represent the R(4 of amino-NR(3)), R(3) and R(4) identical or different, be H, C
1-C
6-alkyl, C
3-C
7-cycloalkyl, perhaps R(3) be phenyl-(CH
2)
p-(P equals 0,1,2,3 or 4) or phenyl, this phenyl or be not substituted or done and replace or two replacements: fluorine, chlorine, methyl or methoxy by following group; R(3) and R(4) also can be C straight chain or side chain jointly
4-C
7-methene chain, wherein one-CH in the methene chain
2-can be by oxygen, sulphur or NR(5) replace, R(5) can be hydrogen or low-carbon alkyl,
R(1) or R(2) can be other substituting group, H, F, Cl, C
1-C
4-alkyl, C
1-C
4Alkoxyl group, CF
3, CmF
2m+1-CH
2-, benzyl or phenoxy group, phenyl or be not substituted wherein, or replaced by one or two following substituting group: methyl, methoxyl group, fluorine or chlorine, m are 1,2 or 3.If contain asymmetric center in the substituent R (1)～R(4),
Then The compounds of this invention can be the S configuration and also can be the R configuration.Compound can be an optical isomer, diastereomer, racemic modification or their mixture.
Alkyl is straight chain both, also can be side chain.
The preferred compound of formula I is: two substituent R (1) or R(2) in one of be the R(4 of amino-NR(3)), R(3 wherein) and R(4) be a methene chain (CH jointly
2)
n, n=4～5.Corresponding another R(1) and R(2) be chlorine or phenoxy group.
Particularly preferably be 4-chloro-3-(1-pyrrolidyl)-benzoyl guanidine, 4-methyl-3-(1-pyrrolidyl)-benzoyl guanidine, 4-chloro-3-(1-piperidyl)-benzoyl guanidine, 4-methyl-3-(1-piperidyl)-and benzoyl guanidine, 4-phenoxy group-3-(1-pyrrolidyl)-benzoyl guanidine, 4-(2-chlorophenoxy)-the 3-(1-pyrrolidyl)-benzoyl guanidine and their pharmaceutical salts.
Chemical compounds I is the acylguanidines that replaces.
The typical ester of representing the acylguanidines class is a pyrazines derivatives ammonia chloropyrazine, and it is used for the treatment of as the hydragog(ue) that potassium stores, and has also narrated the multiple compound of ammonia chloropyrazine class in the literature, for example dimethylamino chloropyrazine or ethyl sec.-propyl ammonia chloropyrazine.
Ammonia chloropyrazine: R ', R "=H
Dimethylamino chloropyrazine: R ', R "=CH
3
Ethyl sec.-propyl ammonia chloropyrazine: R '=C
2H
5, R "=CH(CH
3)
2
In addition, studies show that the ammonia chloropyrazine has antiarrhythmic effect (circulation, 79:1257-63(1989)).Yet can not be widely used as anti-arrhythmic, Ruo ， And follows blood pressure drops and the effect of short urine salt excretion because this acts on very, and this side effect in the treatment irregular pulse is undesirable.
The antiarrhythmic effect of ammonia chloropyrazine is confirmed (European heart journal 9(mending 1) in the experiment of the animal hearts that exsomatizes: 167(1988)), for example experiment showed, with rat heart that the ventricle that manually causes trembles can be stoped fully by the ammonia chloropyrazine.Above mentioned ammonia chloropyrazine derivative ethyl sec.-propyl ammonia chloropyrazine is stronger than ammonia chloropyrazine for this model.
In U.S. Pat 3780027, announced acidylate guanidine class; it is compound with formula I similar; be trisubstituted benzoyl guanidine class with the fundamental difference of The compounds of this invention I; its substitute mode has important amino to make it have the effect of anti-short urine salt excretion from the hydragog(ue) that can buy such as bumetanide and furan rice thiophene And at 2 of the carbonyl guanidine radicals and 2 bit strips, and these compounds reports have very strong short urine salt excretion effect.
At European patent EP 91416499(HOE89/F288) announced the benzoyl guanidine class, at R(2) corresponding position on the group has SO
nBase, they have only antiarrhythmic effect.
The compounds of this invention but unexpectedly show do not have do not wish favourable and the effect of disadvantageous short urine salt excretion; for example occurring still having good anti-arrhythmia character under the anoxybiotic state; these compounds are because its pharmacological action is suitable for highlightedly as the anti-arrhythmic with prevention and treatment myocardial infarction and the anginal cardioprotection of treatment, and also preventability ground suppresses or stop greatly the pathophysiological process that irregular pulse caused that damage that ischemic causes or ischemic cause.Because of pathologic anoxic and ischemia condition are had the formula I compound of the present invention of provide protection owing to suppress the Na of cell
+/ H
+Exchanging mechanism can be used as medicine and is used for treating acute or damage that chronic ischemia causes or former or the secondary disease that therefore causes.This is applicable to the surgical operation medication; for example during organ transplantation; both can before exteriorizing or in the middle of the operation, be protected the organ of contributing; for example in the protection of handling or leaving the organ of the excision in the physiology body lotion in; also can be used for accepting the process of transplant organ; these compounds also are valuable protection medicines carrying out aspect the angioplasty, for example in cardiovascular and peripheral vascular plastic operation.These compounds are suitable for as neural ischemic because the damage that ischemic is caused has provide protection, and particularly the central nervous system ischemic is for example treated cerebral seizure or cerebral edema.In addition, formula I compound of the present invention also is suitable for treating various shocks, anaphylactic shock for example, and cardiogenic shock, circulating blood volume reduce property shock and bacillary shock.
In addition, the effect that formula I compound of the present invention also has effective inhibition cytodifferentiation, the differentiation of for example fibroblastic differentiation and vascular smooth muscle cell, the valuable curative of the disease that the cytodifferentiation of former or secondary reason of can be used as formula I compound causes, thereby can be used as antiatherosclerotic, the advanced diabetes syndromes, malignant neoplastic disease, for example pulmonary fibrosis disease of fibrosis, hepatic fibrosis disease or renal fibrosis disease, and organ is loose and organ hyperplasia, particularly prostatomegaly or hyperplasia.
The compounds of this invention is sodium in the cell-hydrogen exchange (Na
+/ H
+Exchange) effective inhibitor, this exchange results from the many kinds of diseases (mainly being hypertension, arteriosclerosis, diabetes or the like), even in those cells of measuring easily, for example red corpuscle, thrombocyte or white corpuscle.Thereby The compounds of this invention can be used as good, easy and the instrument medicine of science, for example is used for diagnosis and determines dissimilar hypertensive differences, also can be used for arteriosclerosis, diabetes and proliferative illness etc.In addition, formula I compound is suitable for that also hypertension is had shortsightedness therapeutic action, and for example the primary blood pressure increases.
The invention still further relates to the preparation method of chemical compounds I, it is characterized in that, with the guanidine reaction of formula II compound and formula III,
R(1 in the formula) and meaning R(2) the same, X is the group of easily leaving away by nucleophilic substitution.
The active carboxylic acid derivative of formula II, wherein X is an alkoxyl group, methoxyl group preferably, phenoxy group, thiophenyl, methylthio group, 2-pyridine sulfenyl, or nitrogen heterocyclic ring (preferably 1-imidazolyl), (the formula II X=Cl) obtains by acyl chlorides own easily with known method.(the formula II X=OH) makes with for example using the thionyl chloride reaction the available again known method of the latter by basic carboxylic acid.
Except the acyl chlorides (X=Cl) of formula II, the active carboxylic acid derivative of formula II can directly (the formula II X=OH) be produced, for example the X=OCH of formula II by benzoic acid derivative own with known method
3Methyl esters be in methyl alcohol, to handle with gaseous state HCl, the acyl imidazoles of formula II is and N,N'-carbonyldiimidazole (X=1-imidazolyl, Staab, Angew, Chem Int Ed Engl 1,351-367, (1962)).With Cl-COOC
2H
5Or the reaction in inert solvent and in the presence of the triethylamine of the mixed acid anhydride II of Tosyl chloride, also available dicyclohexylcarbodiimide (DCC) activates phenylformic acid.At the Advanced Organic Chemistry that J.March compiles, the third edition (John Wiley ﹠amp; Sons, 1985) a series of preparation methods of the active carboxylic acid derivative of formula II have been narrated in 350 pages.
The active carboxylic acid derivative of formula I and the guanidine of formula III by currently known methods in protic or non-proton property but react in the organic solvent inert, these solvents are proved and are applicable to methyl benzoate (II, X=OMe) carry out with being reflected among methyl alcohol or the THF of guanidine, temperature is 20 ℃ and arrives between the boiling point of solvent for use, the great majority of compound ii and guanidine III (as free alkali) be reflected at carry out in the non-proton property inert solvent favourable, as THF, glycol dimethyl ether diox, but the reaction of II and III also can be carried out in water.
When X=chlorine, the adding acid scavenger is more favourable during operation, for example comes in conjunction with hydrochloric acid with excessive guanidine.
The guanidine of the basic benzoic acid derivative of formula II and used formula III is known, states in the literature.The unknown compound of formula II can for example use dicarboxylic acid anhydride such as Pyroglutaric acid or Succinic anhydried by the known method preparation of document, and with methyl benzoate II (wherein R(1), R(2) as above definition R(3), R(4) is H, and X is OCH
3) be transformed into and will have the compound of top definition IV, wherein R(1) or R(2) be the cyclic imide of formula IV a.The n of methene chain equals 3 to 7.
This imines IV a reacts with sodium borohydride and boron trifluoride-ether then, generates corresponding formula IV
6Methyl benzoate, it can be further directly reacts the compound of production I with guanidine.
Benzoyl guanidine is weak base normally, can combine salify with acid.Can consider all medicinal acid as acid-adducting salt, for example contain particularly hydrochloride of haloid acid, lactic acid salt, vitriol, the Citrate trianion tartrate, acetate, phosphoric acid salt, methane sulfonates is right-tosylate.
The medicament that contains chemical compounds I can be oral, the intestines and stomach externally applied agent, and intravenous injection, rectal administration or inhaled medication are preferably selected for use according to the state of an illness.Chemical compounds I can be used separately or share with the auxiliary agent of Galenicals, but can also human for animals.Which type of auxiliary agent is suitable for desired pharmaceutical dosage form, and this knows based on their expertise for those skilled in the art, except solvent, wedding agent, suppository base, outside the carrier of additive of tablet and other effective constituent, also available for example oxidation inhibitor, dispersion agent, emulsifying agent, foam killer, correctives, sanitas, solubility promoter or tinting material.
Formulation for oral use is that peculiar effect compound mixes with the additive that suits, and as vehicle, stablizer or inert diluent, makes suitable formulation with ordinary method, as tablet, and dragee, capsule, water-based, alcohol or oil-based solvent.Inert excipients is for example used gum arabic, magnesium oxide, magnesiumcarbonate, potassiumphosphate, lactose, glucose or starch, particularly W-Gum.The also available wet grain method of both available dry granular during manufacturing, oiliness auxiliary material or can be with for example vegetables oil or animal oil, as sunflower oil or Oils,glyceridic,cod-liver as the oiliness lysate.
Subcutaneous or intravenous injection medication is that active compound and conventional substances such as solubility promoter, emulsifying agent or other auxiliary agent are made solution, suspension or emulsion.Solvent can consider have: water, normal saline solution or alcohols, and as ethanol, propyl alcohol, glycerine, available in addition sugar soln, as glucose solution or mannitol solution, the also mixed solution of available above-mentioned all kinds of SOLVENTS.
For making the pharmaceutical dosage form of aerosol or sprays, be suitable for active substance to mix in medicinal compatible solvent with the formula I, for example make solution, suspension agent or emulsion, solvent especially with ethanol or water for well, or the mixed solution of available these solvents.
Also can contain other medicinal auxiliary agent, for example tensio-active agent, emulsifying agent and stablizer and jet flow stream in the preparation as required.The concentration that such preparation generally contains active substance is approximately 0.1～10%, particularly about 0.3～3%(weight).
Take the formula I active substance dosage and take action intensity and the acting duration that frequency depends on compound used therefor, in addition, also depend on the kind and the state of an illness of disease, and subject mammiferous kind age, body weight and individual situation.
Formula I compound dosage every day is that the patient of 75Kg on average is at least 0.001mg to about body weight, is preferably 0.01mg to 10mg, preferably 1mg.In fact during the disease acute attack, must be with higher than usual dosage after for example myocardial infarction takes place, for example every day 4 dosage units, particularly when intravenous injection is used, need arrive 100mg for degree of depth infarct victims dosage every day.
Experimental section
The X of formula II is OCH
3Compound generate the logical method (method A) of reaction of benzoyl guanidine hydrochloride I
Method A:
0.02mol the methyl esters II is dissolved in methyl alcohol 50ml, reacts with 3.6g guanidine (free alkali) under argon shield.Reflux 12h removes under reduced pressure and desolvates, and uses the water treatment residuum, dichloromethane extraction, steaming desolventizes, and gets the oily residuum, be dissolved in methyl alcohol HCl, add ether and make and tell oily matter, oily matter is with the silica gel column chromatography (eluent: methylene chloride 20: 1) of purifying.
By phenylformic acid (II, X=OH) the logical method (method B) of preparation benzoyl guanidine I
Method B:
The benzoic acid derivative 0.01mol of general formula II (X=OH) dissolves or is suspended among the anhydrous THF of 60ml, then with 1.78g(0.011mol) the carbonyl dimidazoles reaction, stir after 2 hours under the room temperature, in reaction solution, add 2.95g(0.05mol) guanidine, stirring is spent the night, and removes the THF(rotatory evaporator under reduced pressure), the residuum water treatment, regulate PH6-7 with 2N hydrochloric acid, the benzoyl guanidine derivant (formula I) that leaching generates.
The benzoyl guanidine that obtains like this can with water-based or methyl alcohol hydrochloric acid or other medicinal acid treatment, be transformed into corresponding salt.
Cyclic imide IV a0.05mol is dissolved in the 50ml diglyme, with 14.1ml(0.1144mol) BF
3Et
2The O reaction is cooled to 0-5 ℃, adds 4.3g(0.1144mol) NaBH
4, temperature is no more than 5 ℃, the 6h that under 5 ℃, stirs the mixture, and in the impouring frozen water, the oil of separating out is used ethyl acetate extraction, MgSO through inclining separately then
4Drying, steaming desolventizes and obtains the product that desire is wanted, and generally need not be further purified the reaction that can generate acidylate guanidine I.
The logical method for preparing cyclic imide IV a by amine IV b
0.1mol the amine of formula IV b and 0.3mol dicarboxylic acid anhydride are total to 180 ℃ of heat fusings as Succinic anhydried or Pyroglutaric acid, and 10 hours, add methyl alcohol and make its dissolving, in water, stir the crystallization ， And ethyl alcohol recrystallization that suction strainer is separated out.
Embodiment 1
4-phenoxy group-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By the reaction of 4-phenoxy group-3-N-pyrrolidyl methyl benzoate and guanidine, m.p225～227 ℃; MS:M(+)=324(calculates molecule amount 324.37), method A.
Embodiment 2
4-methyl-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By 4-methyl-3-N-pyrrolidyl methyl benzoate and guanidine reaction (method A) m.p.235-238 ℃; MS:M
+=226(calculates molecular weight: 226.67)
Embodiment 3
4-chloro-3-N-ethylamino-benzoyl guanidine hydrochloride
By 4-chloro-3-N-ethylamino-methyl benzoate and guanidine reaction (method A), m.p.196-198 ℃; MS:M
+=240(calculates molecular weight: 240.69).
Embodiment 4
4-phenoxy group-3-N-Propylamino benzoyl guanidine hydrochloride
By 4-phenoxy group-3-Propylamino methyl benzoate and guanidine reaction (method A).M.p.221～223 ℃; MS:M
+=312(calculates molecular weight: 312.36).
Embodiment 5
4-chloro-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By 4-chloro-3-N-pyrrolidyl methyl benzoate and guanidine reaction (method A).M.p.268-270 ℃; MS:M
+=358(calculates molecular weight: 266.73)
Embodiment 6
4-methoxyl group-3-N-Propylamino benzoyl guanidine hydrochloride
By 4-methoxyl group-3-N-Propylamino methyl benzoate and guanidine reaction (method A).M.p.231～233 ℃; MS:M
+=250(calculates molecular weight: 250.30)
Embodiment 7:
4-chloro-3-N-benzamido group benzoyl guanidine hydrochloride
By 4-chloro-3-N-benzamido group methyl benzoate and guanidine reaction (method A).M.p.91-93 ℃; MS:M
+=302(calculates molecular weight: 302.76)
Embodiment 8
The 4-(2-chlorophenoxy)-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By the 4-(2-chlorophenoxy)-3-N-pyrrolidyl methyl benzoate and guanidine reaction (method A).M.p.121 ℃; MS:M
+=358(calculates molecular weight: 358.82).
Embodiment 9
4-(2, the 3-dichlorophenoxy)-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By 4-(2, the 3-dichlorophenoxy)-3-N-pyrrolidyl methyl benzoate and guanidine reaction (method A).M.p.169～170 ℃; MS:M
+=391(calculates molecular weight: 393.27).
Embodiment 10
The 4-(2-methylphenoxy)-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By the 4-(2-methylphenoxy)-3-N-pyrrolidyl methyl benzoate and guanidine reaction (method A).M.p.185～200 ℃; MS:M
+=338(calculates molecular weight: 338.4).
Embodiment 11
The 4-(4-chlorophenoxy)-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By the 4-(4-chlorophenoxy)-3-N-pyrrolidyl methyl benzoate and guanidine reaction (method A).M.p.120～135 ℃; MS:M
+=358(calculates molecular weight: 358.82)
Embodiment 12:
4-(2-methoxyl group phenoxy group)-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By 4-(2-methoxyl group phenoxy group)-3-N-pyrrolidyl methyl benzoate and guanidine reaction (method A).Mp:180-195 ℃; MS:M
+=354(calculates molecular weight 354.4).
Embodiment 13:
4-(3-pyrroles's oxygen base)-3-N-pyrrolidyl benzoyl guanidine hydrochloride
By 4-(3-pyrroles's oxygen base)-3-N-pyrrolidyl methyl benzoate and guanidine reaction (method A).Mp:＞250 ℃; MS:M
+=325(calculates molecular weight: 325.36).
Embodiment 14:
4-chloro-3-N-piperidyl benzoyl guanidine hydrochloride
By 4-chloro-3-N-piperidyl methyl benzoate and guanidine reaction (method A).Mp:210-212 ℃; MS:M
+=280(calculates molecular weight: 280.76).
Embodiment 15:
4-methyl-3-N-piperidyl benzoyl guanidine hydrochloride
By 4-methyl-3-N-piperidyl formic acid methyl esters and guanidine reaction (method A).Mp::160-162 ℃; MS:M
+=260(calculates molecular weight: 260.33).
Embodiment 16:
4-chloro-3-N-amylamine base benzoyl guanidine hydrochloride
By 4-chloro-3-N-amylamine yl benzoic acid methyl esters and guanidine reaction (method A).Mp:80-82 ℃; MS:M
+=282(calculates molecular weight: 282.77).
Embodiment 17:
4-dimethylin benzoyl guanidine hydrochloride
By 4-dimethylin phenylformic acid and guanidine reaction (method B), be colourless crystallization, mp:＞285 ℃.
Embodiment 18:
4-piperidyl benzoyl guanidine hydrochloride
By 4-piperidyl phenylformic acid and guanidine reaction (method B), be colourless crystallization, mp:189 ℃.
Embodiment 19:
3-chloro-4-piperidyl benzoyl guanidine hydrochloride
By 3-chloro-4-piperidyl phenylformic acid and guanidine reaction (method B), be colourless crystallization, mp:155 ℃.
Embodiment 20:
4-N-methyl-N-(2-styroyl) amido benzoyl guanidine acetate
By 4-N-methyl-N-(2-styroyl) amido phenylformic acid and guanidine reaction (method B), colourless crystallization, mp:173 ℃.
Pharmacological datum
The anesthetized rat of coronary artery ligation
A) method
Male Sprague Dawley rats by intraperitoneal injection thiopentone dosage is 100mg/kg, after opening chest and strutting, cuts the left side coronary artery, by an AT pin silk thread is guided to round the left side coronary artery.After 10 minutes balance period, vein is tried material, with silk thread coronary artery is tightened after 5 minutes.According to the criterion measuring cell premature contraction of Lambeth agreement (London, 1987), ventricular tachycardia and ventricle tremble.Tried material administration in the DMSO/ salt solution, containing DMSO in the solution is 1% volume.The control group laboratory animal is only given solvent.The solvent volume of Zhu Ruing is 1ml/kg in all cases.
B) result
When being 1mg/kg by the material dosage of embodiment 8, the time length of ventricular tachycardia is 4 ± 2 seconds (n=6), and the control group of medication is not 41 ± 19 seconds (n=4).
Claims (5)
1, the method for the benzoyl guanidine of preparation formula I and pharmaceutical salts thereof
In the formula:
R (1) or R (2) be amido-N (R3) (R4),
R (3) and R (4) are identical or different, are hydrogen, C
1-C
6-alkyl, C
3-C
7-cycloalkyl, or
R (3) equals phenyl-(CH
2)
P is 0,1,2,3 or 4, or phenyl, and phenyl is not for being substituted or being replaced by following one or two groups:
Fluorine, chlorine, methyl or methoxy,
R (3) and R (4) can be the C of straight or branched jointly also
4-C
7Methylene radical, wherein one of methene chain-CH
2-, can be by oxygen sulphur or NR (5) displacement,
R (5) is hydrogen or low-carbon alkyl,
R (1) or R (2) can be other substituting group and replace H, F, Cl, C
1-C
4-alkyl, C
1-C
4-alkoxyl group, CF
3, CmF
2M+
1-CH
2-, benzyl or phenoxy group, on the phenyl or be not substituted or replaced by following one or two groups: methyl, methoxyl group, fluorine or chlorine, m are 1,2 or 3.
This preparation method's feature is, with the compound of formula II and the guanidine reaction of formula III
The implication of R in the formula (1) and R (2) is the same, and X is for easily making the leavings group of nucleophilic substitution.
2, according to the method for the benzoyl guanidine of the preparation formula I of claim 1, it is characterized in that, two substituent R (1) or R(2) in one of be the R(4 of amido-NR(3)), R(3 wherein) and R(4) be a methene chain (CH jointly
2)
n, n=4-5, another corresponding R(1) or R(2) be chlorine or phenoxy group.
3, according to the method for the benzoyl guanidine of the preparation formula I of claim 1, it is characterized in that:
4-chloro-3-(1-pyrrolidyl)-benzoyl guanidine,
4-methyl-3-(1-pyrrolidyl)-benzoyl guanidine,
4-chloro-3-(1-piperidyl)-benzoyl guanidine,
4-methyl-3-(1-piperidyl)-benzoyl guanidine,
4-phenoxy group-3-(1-pyrrolidyl)-benzoyl guanidine and
4-(2-chloro phenoxy group-3-(1-pyrrolidyl)-benzoyl guanidine and their pharmaceutical salts.
4, the chemical compounds I according to claim 1 is used for the ARR medicine of preparation treatment.
5, be used to prepare the medicine of Cardioprotective according to the chemical compounds I of claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4204557.0 | 1992-02-15 | ||
| DE4204557 | 1992-02-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1075960A true CN1075960A (en) | 1993-09-08 |
| CN1036267C CN1036267C (en) | 1997-10-29 |
Family
ID=6451796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93101526A Expired - Fee Related CN1036267C (en) | 1992-02-15 | 1993-02-15 | Amino-subst.-benzoyl guanidines, a process for production thereof, use as drug thereof and drug containing it |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1036267C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1062554C (en) * | 1995-07-26 | 2001-02-28 | 赫彻斯特股份公司 | Substituted guanidine cinnamate, its prepn., its application as medicine or diagnosing agent and medicine containing the compound |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3780027A (en) * | 1970-04-29 | 1973-12-18 | Merck & Co Inc | Anthranilic acid derivatives |
| DE3929582A1 (en) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICINE AND THE MEDICINE CONTAINING IT |
-
1993
- 1993-02-15 CN CN93101526A patent/CN1036267C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1062554C (en) * | 1995-07-26 | 2001-02-28 | 赫彻斯特股份公司 | Substituted guanidine cinnamate, its prepn., its application as medicine or diagnosing agent and medicine containing the compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1036267C (en) | 1997-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1049888C (en) | Benzoylguanidine, process for preparing same, their use as medicine and medicine containing same | |
| EP0442820B1 (en) | Benzimidazole and azabenzimidazole derivatives, thromboxane receptor antagonists, processes for their preparation, synthesis intermediates, compositions containing them | |
| JP3231042B2 (en) | Nitrate ester of 2- (2,6-di-halo-phenylamino) phenylacetic acid derivative and method for producing the same | |
| CN1073988C (en) | Substituted N-heteroaroaroylguanidin, preparation, pharmaceutical application and medicine containg same | |
| CN1064954C (en) | Orthosubstituted benzoylguanidine, preparation of same, pharmaceutical containing same and application of same | |
| CN1041203C (en) | Pyrazolopyridine compound and processes for preparation thereof | |
| HU184966B (en) | Process for producing phenyl-piperazine derivatives of anti-agression activity | |
| JP6507267B2 (en) | Heterocyclic alkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions containing the same | |
| CN1122329A (en) | Phenyl-substituted alkenylcarboguanidides carrying perfluoroalkyl groups, a process for their preparation, their use as a medicament or diagnostic agent, and also a medicament containing them | |
| DE3525284A1 (en) | NEW CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| EP0022118A1 (en) | Derivatives of sulfonyl aniline, process for their preparation and their use in therapy | |
| EP0092458A2 (en) | Imidazo(1,2-a)pyridine derivatives, their preparation and use in therapeutical products | |
| EP1966173B1 (en) | Heterocyclic derivatives, preparation and therapeutic use thereof | |
| JP2558208B2 (en) | Indane derivative and thromboxane antagonist containing the compound | |
| FR2565587A1 (en) | NOVEL DERIVATIVE OF N-ACYLIC ACIDIC ACID AMINO ACID DIAMIDE, A SALT THEREOF, A PROCESS FOR PRODUCTION THEREOF AND AN ANTI-ULCEROUS AGENT CONTAINING THE SAME | |
| JPS6210057A (en) | Drug | |
| CN1302205A (en) | Use of benzofuroxan derivatives in treating angina pectoris | |
| CN1119643A (en) | Benzoylguanidines substituted by heterocyclic N-oxide, process for their preparation, their use as a medicament or diagnostic agent, medicament containing them and intermediate products for their ... | |
| CN1119183A (en) | Ortho-amino-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic agent, and also a medicament containing them | |
| CN1117962A (en) | Arylbenzoylguanidin | |
| CN1075960A (en) | Amino benzoyl guanidine, its preparation method that replaces is as the purposes and the medicament that contains it of medicine | |
| CN1061648C (en) | Antiarrhythmic and cardioprotective substituted indenoyiguanidines | |
| EP0246126A1 (en) | Benzimidazoles and imidazopyridine sulfone amides, process for their preparation and their use as medicaments | |
| CN1062859C (en) | Substd. 1-naphthoyl guanidines, their preparing method, use and drug contg. them | |
| JPH0471067B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |